FATE Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own FATE shares is 232, representing 100.32% of the company's common stock.

VESTAL POINT CAPITAL, LP, in the last quarter, reduced its stake in FATE by -37.98% restricting it's holding to 800 thousand shares of worth nearly $5.87M. BLACKROCK INC. also lessened -18.84% of the FATE shares from its portfolio, reducing its holding to 9.1 million shares of worth $66.79M. D. E. SHAW & CO., INC. also shunned FATE shares holding by -23.76% last quarter which brought its holding to 2.73 million shares worth $20.05M.

As per its latest 13F filing, MORGAN STANLEY increased its stake in FATE by 132.02% in the last quarter. The institutional holder raised its holding to 3.07 million shares having worth more than $22.50M. SCHONFELD STRATEGIC ADVISORS LLC also added 78.29% more shares of FATE to its portfolio, raising its holding to 886.93 thousand shares of worth $6.51M. SOLEUS CAPITAL MANAGEMENT, L.P. also increased its FATE shares holding by 100% which brought its holding to 870 thousand shares worth $6.39M.

The insider with the most stakes in FATE is Redmile Group, LLC , at the company. Additionally, FATE stock is highly held by President and CEO Wolchko J Scott and President and CEO Valamehr Bahram among others.

Company executives, directors, and other insiders own 2.28% percent of Fate Therapeutics, Inc.'s stock. Within the last six months, there have been 4 transaction(s) in which FATE insiders have sold stock, totaling 361.97K shares. Insiders that have sold shares include VALAMEHR BAHRAM, BRESSI JEROME CHARLES, and TAHL CINDY.

There have been 0 transaction(s) during the past 6-months in which Fate Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 13.44M Fate Therapeutics, Inc. shares are held by insiders, which represents about 2.28% of FATE stock.

FATE , Redmile Group, LLC holds the largest portfolio of the company's shares. FATE shares owned by Redmile total nearly 12.49 million.

MORGAN STANLEY is the largest institutional owner in FATE which holds 3.07 million shares worth $22.50M or 3.12% of the total FATE shares outstanding followed by SCHONFELD STRATEGIC ADVISORS LLC with ownership of 886.93 thousand shares representing 0.9% of the FATE ownership. SOLEUS CAPITAL MANAGEMENT, L.P. is the third largest stakeholder with 870 thousand shares or 0.88% of the ownership worth more than $6.39M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the FATE is concerned, it is a stock which is optionable.

Number of FATE shares short is 11.20M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 113.89M shares of FATE are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, FATE has 98.79M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for FATE is 3.23.